ClinicalTrials.Veeva

Menu

Comparison of Vaginal and Intramuscular Progesterone in Vitrified-warmed Blastocyst Transfer Cycles

Mass General Brigham logo

Mass General Brigham

Status and phase

Withdrawn
Phase 4

Conditions

Infertility

Treatments

Drug: Intramuscular Progesterone
Drug: Vaginal progesterone gel (Crinone® 8%)

Study type

Interventional

Funder types

Other

Identifiers

NCT02772120
BWH2016progRCT

Details and patient eligibility

About

The aim of this study is to test the hypothesis that the pregnancy rates of women (ages 18-50 years) undergoing transfer of vitrified-warmed blastocysts (frozen at less than 41 years of age) as part of their IVF treatment are not different with respect to the administration of progesterone (Crinone® 8% vaginal gel versus intramuscular progesterone).

Full description

The hypothesis of this study is that the type of progesterone administered (intramuscular progesterone or Crinone® 8% vaginal gel) does not affect implantation and clinical pregnancy rates in women receiving cryo-thawed blastocysts that were produced using their own eggs and frozen before age 41 years. Both intramuscular progesterone (25-100 mg compounded in oil) or vaginal progesterone (Crinone® 8% vaginal progesterone gel) are widely used for luteal phase support in patients receiving vitrified-warmed embryos. Crinone® 8% is FDA approved for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency (FDA approval letter, 1997).

Sex

Female

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Signed informed consent
  • Patient age at time of embryo freezing: 18 to 40.9 years
  • Patient age at embryo transfer: 18 to 50 years (i.e. women currently ages 18-50 years who are transferring embryos created using eggs retrieved from women aged 18-40.9 years)
  • Blastocysts frozen by vitrification at Brigham and Women's Hospital
  • Standard eligibility criteria for blastocyst transfer at Brigham and Women's Hospital

Exclusion criteria

  • Fresh or cleavage-stage embryo transfer planned
  • Gestational carrier cycles
  • Natural and modified natural cycles
  • Embryos frozen more than once or derived from thawed oocytes
  • Embryos frozen at centers other than Brigham and Women's Hospital
  • Embryos frozen using techniques other than vitrification (i.e. slow frozen)
  • Patients with recurrent pregnancy loss, defined as failure of 3 or more clinical pregnancies
  • Uterine factor infertility: Asherman's, submucosal fibroids, polyp greater than 1 cm at time of embryo transfer, uninterrupted hydrosalpinx
  • Patients with three prior failed embryo transfers (fresh or frozen)
  • BMI<18 or >40 kg/m2 at screening
  • Currently breast feeding or pregnant
  • Embryo biopsy performed
  • Current smoking, alcohol or illicit drug use
  • Allergy to study drugs
  • Refusal or inability to adhere to study protocol
  • Participation in other experimental drug trials concurrently within the past 60 days

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

0 participants in 2 patient groups

Vaginal progesterone gel (Crinone® 8%)
Active Comparator group
Description:
Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
Treatment:
Drug: Vaginal progesterone gel (Crinone® 8%)
Intramuscular Progesterone
Active Comparator group
Description:
Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
Treatment:
Drug: Intramuscular Progesterone

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems